Homepage - Ophthalmology Advisor
Researchers and experts detail the links between ocular conditions and attention deficit hyperactivity disorder, as well as its associated behaviors such as chronic eye rubbing, in both children and adults.
FDA Drug Approval Decisions Expected in December 2024
Nov 15, 2024 · The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA) and making a final decision on marketing approval. The typical period for review is 10 months after the drug application has been accepted by the Agency.
Photobiomodulation Treatment for Dry AMD Approved By FDA ...
Nov 15, 2024 · A photobiomodulation therapy device has received approval by the US Food and Drug Administration (FDA) to be marketed for the treatment of nonexudative (dry) age-related macular degeneration (AMD), according to statements from the FDA and the manufacturer.The device allows physicians the opportunity to offer a noninvasive treatment for dry AMD with a low-level laser therapy (LLLT) technology. 1,2
Advanced Retinitis Pigmentosa Loss May Be Recoverable
Oct 20, 2024 · As a result, participants in the high-dose gene therapy arm improved from baseline to week 52 by a mean of 0.337±0.0829 logMAR, which is significant compared with those who received sham therapy (P =.0209).. Notably, 76-week gains reached 0.539±0.1032 logMAR, also substantial in comparison with placebo (P =.0014).Patients with low-dose had 52-week progress of 0.382±0.1244 logMAR (P =.0290 ...
Ocular Myasthenia Gravis Treatment Options Explained
Jul 20, 2023 · Myasthenia gravis (MG) can occur in 2 forms: a generalized myasthenia gravis (GMG) or purely ocular myasthenia gravis (OMG). Ocular myasthenia gravis is characterized by progressive fatigability of skeletal muscle limited to the orbicularis oculi, levator palpebrae superioris, and the extraocular muscles. 1 Up to half of patients diagnosed with MG present with ocular muscle weakness before ...
Macular Telangiectasia Type 2 Implant Has Strong Tolerability ...
Oct 18, 2024 · Intraocular implantation of NT-501 (Neurotech Pharmaceuticals, Inc.) — a cell therapy treatment for patients with macular telangiectasia type 2 — is well-tolerated and correlates with a lower percentage of eyes with ellipsoid zone (EZ) loss, according to a poster presented at the American Academy of Ophthalmology’s 2024 Annual Meeting held in Chicago, from October 18 to 21, 2024.
Ophthalmology CME/CE Courses - Ophthalmology Advisor
myCME is the premier destination for continuing medical education (CME) and continuing education (CE), committed to providing high-quality, evidence-based, and user-friendly courses tailored to the needs of physicians, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals across 20+ specialties.. Below you’ll find practice-relevant ophthalmology ...
Methotrexate May Lower Risk of Retinal Detachment Repair …
Dec 17, 2024 · Systemic methotrexate and azathioprine therapies are associated with a lower risk of proliferative vitreoretinopathy (PVR) development within 6 months of primary retinal detachment, according to the results of a multicenter retrospective cohort study published in Ophthalmology Retina.. PVR is a predominant cause of failure for repair of retinal detachment.
Photodynamic Therapy Modifications Equally Effective in CSCR ...
Dec 23, 2024 · Both half-dose and half-fluence photodynamic therapy (PDT) appear comparably safe and effective in treating chronic central serous chorioretinopathy (cCSCR); both achieving similar short-term structural and functional results, according to a systematic review and meta-analysis published in American Journal of Ophthalmology.Consequently, physicians can more readily customize their approach to ...
Eye Shape Deformity May Predict Progression of Myopic …
Dec 19, 2024 · Eye shape deformity can be used to help predict progression of myopic maculopathy (MM), according to research published in Retina.The research team used 3-dimensional magnetic resonance imaging (3D MRI) to demonstrate the predictive capabilities of eye shape in patients with high myopia.